Protea Biosciences Group, Inc. (“Protea”) announced today that Princeton University has purchased Protea’s LAESI DP-1000 Instrument System for direct molecular analysis. The system will be used in Princeton’s Frick Chemistry Laboratory for the screening of microbial samples to identify new molecular entities that may hold promise as new antimicrobial therapeutics.
“We are pleased that Princeton’s Frick Chemistry Laboratory will be applying our proprietary LAESI technology to the discovery of novel antimicrobials and other therapeutic molecules; this is a field that is today of critical importance to the pharmaceutical industry and to global human health,” stated Steve Turner, Protea’s CEO.
“Bacteria use a wide range of small molecules to detect and respond to their environment and to communicate, collaborate, or compete with other microbes. The small molecules underlying this complex chemical language, their functions and biosynthetic pathways, comprise the primary focus of our research efforts, and Protea’s DP-1000 system is an ideal analytical tool that will benefit various aspects of our work,” stated Mohammad Seyedsayamdost, PhD., Associate Professor of Chemistry, Princeton University. He continued, “This group of small molecules has traditionally served as a prolific source of drugs or drug leads, therefore, our studies will also aim to identify therapeutically useful small molecules.”
The LAESI DP-1000 Instrument System allows the direct identification of molecules in living cells and microbial samples, with analysis completed in seconds to minutes.Related Articles: